Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alvocidib - Sanofi-aventis/Sumitomo Pharma America

Drug Profile

Alvocidib - Sanofi-aventis/Sumitomo Pharma America

Alternative Names: Alvocidib hydrochloride; DSP-2033; Flavopiridol; Flavopiridol hydrochloride; HL-275; HMR 1275; IND 46211; L-86-8275; MDL-107826A; NSC 649890

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi-aventis
  • Developer AbbVie; National Cancer Institute (USA); Sumitomo Pharma America; Tolero Pharmaceuticals
  • Class Antineoplastics; Benzopyrans; Chlorinated hydrocarbons; Flavonoids; Ketones; Piperidines; Small molecules
  • Mechanism of Action Cyclin dependent kinase 9 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia; Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; B-cell lymphoma; Chronic lymphocytic leukaemia; Germ cell and embryonal neoplasms; Germ cell cancer; HIV infections; Multiple myeloma; Myelodysplastic syndromes; Non-small cell lung cancer; Oesophageal cancer; Renal cancer; Reperfusion injury

Most Recent Events

  • 10 May 2023 3781050- Intro, KDM updated, dev line forwarded to disconiued
  • 28 Apr 2023 Discontinued - Phase-III for Chronic lymphocytic leukaemia (Second-line therapy or greater) in European Union (IV)
  • 28 Apr 2023 Discontinued - Phase-III for Chronic lymphocytic leukaemia (Second-line therapy or greater) in USA (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top